Altuzumab gives a positive result in Puerto Rican women with multiple sclerosis

This study highlights the importance of investigating MS subtypes in relation to definitions, diagnosis, and treatment.

Dr. Angel Chinya, MD, is the medical director of the Multiple Sclerosis Foundation. Photo: Journal of Medicine and Public Health, Fabiola Plaza.

This time is the case of a 41-year-old woman, diagnosed with multiple sclerosis in 2001 (at age 21) and currently being treated with alemtuzumab, who presented at the San Juan Multiple Sclerosis Center in February 2021 for Outbreak follow-up assessment and active referrals.

On examination, it was found that the patient had weakness bilateral lower extremities wheelchair-assisted, neurogenic bladder, constipation, impaired walking, Loss of coordination and deterioration Moderate cognitive.

“At the current visit, the patient was attentive and oriented to the place, time and person. The medical history included a diagnosis of relapsing multiple sclerosis and a caesarean section. In addition, The patient has a severe infection For VZV at age 12, which led to his hospitalization. The family history included MS in the cousin, a third-degree relative, on the mother’s side,” note the case authors.

They noted that disease-modifying treatments for this patient have changed several times over the years. In 2001, interferon beta1-b was started for seven years, until 2008, when it was changed to natalizumab. He continued using natalizumab for three years, switching to glatiramer acetate in 2011 and then dimethyl fumarate in 2013.

Altuzumab treatment significantly improved the patient’s cognitive abilities, motor control and overall quality of life. Photo: medicines.

“At that time, the patient had experienced more than three relapses in less than two years, which That spurred the recent change. The first dose of alemtuzumab Given in October 2016, second dose in October/2017 and third dose in May/2019,” case details.

They added that altuzumab treatment led to a significant improvement in cognitive abilities, movement control and Total quality of life for this patient.

case link

Specialists explain that patients with highly active, normal and relapsing multiple sclerosis have limited treatment options and it is necessary to study the effectiveness of recovery from deterioration in these patients.

“Discussing this issue allows us to find out Beneficial Results of Altuzumab In patients with highly active relapsing-remitting and relapsing multiple sclerosis. Supports previous disease stabilization findings after alemtuzumab treatment for active multiple sclerosis. They also serve as evidence of clinical improvement and slow progression after the proposed treatment for active or aggressive multiple sclerosis is followed.”

In addition, they conclude that this case serves as informative information about the therapeutic benefits of alemtuzumab in patients with relapsing-remitting multiple sclerosis.

“In particular, this drug appears to be beneficial for those patients with very active MS who have not been able to improve or control their disease with DMT. Reporting these results allows for a review of altuzumab as an effective treatment for patients with MS. Too energetic. . . ” or aggressive. Overall, this study highlights the importance of investigating MS subtypes in relation to definitions, diagnosis, and treatment,” they concluded.

Multiple sclerosis (MS) is a debilitating autoimmune disease that currently affects about 2.8 million people worldwide. It is estimated that 2,387 of them live on the island of Puerto Rico.

Access the status here.